Incremental cost-effectiveness of two zidovudine regimens to prevent perinatal HIV transmission in the United States.
摘要:
Recently concluded clinical trials in Thailand have demonstrated that a short course of zidovudine therapy administered to human immunodeficiency virus-infected women during late pregnancy and labor can substantially reduce the likelihood of perinatal transmission of HIV. This regimen is both less expensive and less effective than the full course of therapy recommended for use in the United States by the U.S. Public Health Service (PHS). The objective of the current study is to estimate the incremental cost-effectiveness of the full-course zidovudine regimen in comparison to the short-course regimen that was tested in Thailand and to determine conditions under which the PHS-recommended regimen produces a net savings in societal resource utilization, relative to the shorter regimen. We used standard methods of incremental cost-effectiveness analysis and derived cost and effectiveness estimates from published studies. The main outcome measure is the incremental cost-effectiveness ratio, which is the additional cost per additional case of perinatal HIV infection averted by the full course of therapy. Full-course zidovudine therapy costs an additional $21,337 per additional case of HIV infection averted, relative to the shorter regimen; this is much less than the cost of treating a case of pediatric HIV infection. Economic and clinical findings both favor full-course zidovudine therapy over short-course therapy to prevent perinatal transmission of HIV in the United States.
收起
展开
DOI:
10.1006/pmed.1999.0601
被引量:
年份:
2000


通过 文献互助 平台发起求助,成功后即可免费获取论文全文。
求助方法1:
知识发现用户
每天可免费求助50篇
求助方法1:
关注微信公众号
每天可免费求助2篇
求助方法2:
完成求助需要支付5财富值
您目前有 1000 财富值
相似文献(242)
参考文献(0)
引证文献(2)
来源期刊
影响因子:4.632
JCR分区: 暂无
中科院分区:暂无